Core Viewpoint - Huali Family's stock price has increased by 5.11% on October 10, reaching 3.50 CNY per share, with a total market capitalization of 5.608 billion CNY, indicating a positive market sentiment towards the company [1] Group 1: Company Overview - Huali Family Co., Ltd. is located at 500 Hongbaoshi Road, East Silver Center, Building B, Changning District, Shanghai, and was established on October 18, 1996, with its listing date on July 9, 2002 [1] - The company's main business involves real estate, innovative technology project investments, and financial project investments, with revenue composition being 96.26% from real estate products, 3.70% from other sources, 0.03% from decoration and greening projects, and 0.02% from graphene derivatives [1] Group 2: Shareholder Information - Among the top ten circulating shareholders of Huali Family, a fund under Southern Fund has increased its holdings in Huali Family by 441,500 shares, totaling 20.4562 million shares, which represents 1.28% of the circulating shares [2] - The Southern CSI Real Estate ETF Initiated Link A (004642) has generated an estimated floating profit of approximately 3.4776 million CNY today, with a floating profit of 1.6365 million CNY during the three-day increase [2] Group 3: Fund Manager Profile - The fund manager of Southern CSI Real Estate ETF Initiated Link A (004642) is Luo Wenjie, who has a cumulative tenure of 12 years and 175 days, managing a total fund size of 138.999 billion CNY [3] - During his tenure, the best fund return achieved was 154.11%, while the worst return was -47.6% [3]

Core Viewpoint - The company, Huayi Family Co., Ltd., is investing approximately RMB 299.99 million to subscribe for 63,157,894 new shares of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. at a price of RMB 4.75 per share, constituting a related party transaction [1][2][6]. Group 1: Transaction Overview - The company signed a subscription agreement on August 10, 2025, to participate in Haihe Pharmaceutical's share issuance, with a total investment not exceeding RMB 300 million [2]. - The company will hold at least 5% of Haihe Pharmaceutical's total shares after the financing is completed [2]. - The company completed the payment of RMB 299,999,996.50 on September 25, 2025, and Haihe Pharmaceutical will proceed with the necessary registration changes [4]. Group 2: Governance and Rights - The company has the right to nominate one observer to the board of Haihe Pharmaceutical, who can attend meetings and provide opinions but does not have voting rights [3]. - The agreement will take effect once all parties have affixed their official seals [3]. Group 3: Strategic Purpose and Impact - The investment aligns with the company's strategy to enhance its core competitiveness and profitability while exploring opportunities in emerging industries [7]. - This strategic financial investment is based on the long-term potential of innovative drugs, aiming to ensure stable operations of the main business while obtaining reasonable financial returns [7]. - The company's financial structure is stable, with a low debt-to-asset ratio, indicating that this investment will not adversely affect its financial and operational status [7].

Core Points - The company Huayi Family announced an investment of RMB 299,999,996.50 (RMB 4.75 per share) to subscribe for 63,157,894 new shares of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1] - This capital increase constitutes a related party transaction as Haihe Pharmaceutical is a subsidiary of the company's controlling shareholder, Shanghai Nanjing Group [1] - As of the announcement date, Nanjing Group holds approximately 11.54% of Haihe Pharmaceutical's shares directly and indirectly through its subsidiary, Tibet Nanjing Enterprise Management Consulting Co., Ltd. [1] - The investment agreement was formalized through a supplementary agreement signed on September 25, 2025, involving Nanjing Group, Tibet Nanjing, and Haihe Pharmaceutical [1]

证券代码：600503 证券简称：华丽家族 公告编号：临2025－034 华丽家族股份有限公司 关于现金增资上海海和药物研究开发股份有限公司 暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、华丽家族股份有限公司（以下简称"公司""华丽家族"）以人民币 299,999,996.50 元（每股人民币 4.75 元）认购上海海和药物研究开发股份有限公 司（以下简称"海和药物""标的公司"）新增股本 63,157,894 股。 2、本次增资事项构成关联交易。海和药物是公司控股股东上海南江（集团） 有限公司（以下简称"南江集团"）的参股公司。截至本公告披露日，南江集团 直接及间接通过其子公司西藏南江企业管理咨询有限公司（以下简称"西藏南江"） 共持有海和药物约 11.54%股权；同时，南江集团董事及股东刘雅娟女士在海和 药物担任董事。根据《上海证券交易所股票上市规则》《上海证券交易所上市公 司自律监管指引第 5 号—交易与关联交易》的规定，本次增资事项构成关联交易。 3、本次交易不构成《上市公司 ...

Core Viewpoint - The stock of Huayi Family has shown significant fluctuations, with a year-to-date increase of 30.38% but a recent decline of 10.32% over the past five trading days [1] Group 1: Stock Performance - As of September 24, Huayi Family's stock price was 3.39 CNY per share, with a market capitalization of 5.432 billion CNY [1] - The stock has experienced a 30.38% increase year-to-date, a 10.32% decrease in the last five trading days, a 13.76% increase over the last 20 days, and a 33.46% increase over the last 60 days [1] - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) five times this year, with the most recent appearance on August 21, where it recorded a net buy of -65.618 million CNY [1] Group 2: Financial Performance - For the first half of 2025, Huayi Family reported an operating income of 138 million CNY, a year-on-year decrease of 11.76%, and a net profit attributable to shareholders of -10.4124 million CNY, a decrease of 437.58% [2] - Cumulative cash dividends since the A-share listing amount to 451 million CNY, with 6.4092 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Huayi Family was 120,400, a decrease of 6.75% from the previous period, with an average of 13,303 circulating shares per shareholder, an increase of 7.24% [2] - The third-largest circulating shareholder is the Southern CSI Real Estate ETF, holding 20.4562 million shares, an increase of 441,500 shares from the previous period [3] Group 4: Business Overview - Huayi Family, established on October 18, 1996, and listed on July 9, 2002, is primarily engaged in real estate, innovative technology project investments, and financial project investments [1] - The revenue composition of the company is 96.26% from real estate products, 3.70% from other sources, 0.03% from decoration and greening projects, and 0.02% from graphene derivatives [1][2]

Group 1 - The core point of the news is that Huayi Family's stock price dropped by 5.08% to 3.36 CNY per share, with a trading volume of 98.45 million CNY and a turnover rate of 1.80%, resulting in a total market capitalization of 5.384 billion CNY [1] - Huayi Family Co., Ltd. is based in Shanghai and was established on October 18, 1996, with its listing date on July 9, 2002. The company's main business includes real estate, innovative technology project investments, and financial project investments [1] - The revenue composition of Huayi Family is primarily from real estate products at 96.26%, with other segments contributing 3.70%, renovation and greening projects at 0.03%, and graphene derivatives at 0.02% [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under Southern Fund is among them. The Southern CSI Real Estate ETF initiated a 441,500-share increase in the second quarter, holding a total of 20.4562 million shares, which accounts for 1.28% of the circulating shares [2] - The Southern CSI Real Estate ETF has a current scale of 173 million CNY and has achieved a year-to-date return of 8.4%, ranking 3597 out of 4220 in its category. Over the past year, it has returned 28.12%, ranking 3282 out of 3814, while since its inception, it has incurred a loss of 39.59% [2] Group 3 - The fund manager of the Southern CSI Real Estate ETF is Luo Wenjie, who has a cumulative tenure of 12 years and 158 days. The total asset scale of the fund is 138.999 billion CNY, with the best fund return during his tenure being 145.85% and the worst being -47.6% [3]

证券代码：600503 证券简称：华丽家族 公告编号：2025-032 华丽家族股份有限公司 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 22 日 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (二)股东大会召开的地点：上海市松江区石湖荡镇三新公路 207 号会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 571 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 152,717,367 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 9.5311 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，董事长王伟林先生主持了会议。本次会议召集、 召开和表决符合《中华人民共和国公司法》及本公司《公司章程》的规定。 ( ...

北京市金杜律师事务所 关于华丽家族股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：华丽家族股份有限公司 北京市金杜律师事务所（以下简称本所）接受华丽家族股份有限公司（以下 简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、《中华 人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上市公司 股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以下简称中国 境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别行政 区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件和现行有效的 公司章程有关规定，指派律师出席了公司于 2025 年 9 月 22 日召开的 2025 年第 二次临时股东大会（以下简称本次股东大会），并就本次股东大会相关事项出具本 法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年第一次临时股东大会审议通过的《华丽家族股份有限公司 章程》（以下简称《公司章程》）； 本所依据上述法律、行政法规、规章及规范性文件和《公司章程》的有关规 定以及本法律意见书出具日以前已经发 ...

证券代码：600503 证券简称：华丽家族 公告编号：临2025－033 华丽家族股份有限公司 第八届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华丽家族股份有限公司（以下简称 "公司"）第八届董事会（以下简称 "本届董事 会"）第一次会议于2025年9月22日通过现场会议合通讯表决的方式召开。经全体董事 一致同意，豁免本次会议通知时间的要求。本次会议由全体董事共同推举王伟林先生 主持，会议应参加表决董事8人，实际参加表决董事8人。本次会议的召集、召开及表 决程序符合《中华人民共和国公司法》《公司章程》及《公司董事会议事规则》等有 关规定。经与会董事审议，表决通过了如下议案： 一、审议并通过《关于选举第八届董事会董事长的议案》 根据与会董事的推举，一致同意选举王伟林先生担任公司董事长，任期与本届董 事会一致。 （表决结果：8 票同意，0 票反对，0 票弃权） 二、审议并通过《关于选举公司第八届董事会专门委员会的议案》 经董事会审议，选举董事会专门委员会成员如下： 董事会战略发展委员会召集人：王伟林 ...

Core Viewpoint - The company Huayi Family announced the results of its first board meeting for the eighth session, which took place on September 22, 2025, and discussed the appointment of the board secretary [1] Group 1: Company Financials - For the year 2024, Huayi Family's revenue composition is as follows: Real estate development accounts for 95.18%, other businesses for 4.68%, landscaping projects for 0.08%, and non-metal mineral products for 0.05% [1] - As of the report date, Huayi Family has a market capitalization of 5.7 billion yuan [1] Group 2: Industry Context - The company is currently facing challenges related to the "blasting mountain" controversy involving its subsidiary, Anta Sports, which has recently appointed a new president for the Greater China region [1]